Key result
Flecainide reduces Ca2+ wave frequency in intact ventricular myocytes without affecting RyR2-dependent sparks.
Why the study?
Flecainide is accepted for CPVT-associated arrhythmias, but whether it directly acts on RyR2 remains controversial.
Flecainide's direct action on RyR2 requires high intracellular concentrations that may not be achieved in intact myocytes, suggesting its antiarrhythmic effects in CPVT may be secondary to Nav1.5 inhibition.
May not achieve direct RyR2 effects in intact myocytes; leaves open Nav1.5 inhibition as primary antiarrhythmic mechanism in CPVT.
Background and purpose: While flecainide is now an accepted treatment for arrhythmias associated with catecholaminergic polymorphic ventricular tachycardia (CPVT), its mechanism of action remains controversial. In studies on myocytes from CPVT mice, inhibition of proarrhythmic Ca 2+ waves was initially attributed to a novel action on the type-2 ryanodine receptor (RyR2). However, subsequent work on wild type (WT) myocytes questioned the conclusion that flecainide has a direct action on RyR2. In the present study, the effects of flecainide were compared in intact and permeabilized WT myocytes. Experimental approach: Intracellular Ca 2+ was measured using confocal microscopy in intact or saponin permeabilized adult rat ventricular myocytes (ARVM). In some experiments on permeabilized cells, flecainide was studied following partial inhibition of the sarcoplasmic reticulum (SR) counter-current. Key results: Flecainide induced sustained changes Ca 2+ sparks and waves in permeabilized ARVM, which were comparable to those reported in intact or permeabilized myocytes from CPVT mice. However, a relatively high level of flecainide (25 μM) was required to induce these effects. Inhibition of the SR counter-current potentiated the effects of flecainide on SR Ca 2+ waves. In intact field stimulated ARVM, prolonged exposure to 15 μM flecainide decreased wave frequency but RyR2 dependent effects on Ca 2+ sparks were absent; higher drug concentrations blocked field stimulation, consistent with inhibition of Nav1.5. Conclusions and implications: In intact ARVM, the absence of effects on Ca 2+ sparks suggests that the intracellular flecainide concentration was insufficient to influence RyR2. Wave inhibition in intact ARVM may reflect secondary effects of Nav1.5 inhibition. Potentiation of flecainide’s action by counter-current inhibition can be explained if transient polarization of the SR membrane during SR Ca 2+ release facilitates its action on RyR2.
No takes yet. Share an insight, caveat, or question.
Steer et al. (2023) studied Catecholaminergic polymorphic ventricular tachycardia (CPVT) mechanisms. Flecainide vs. Vehicle (ethanol, <0.01%) was evaluated on Ca2+ wave frequency and Ca2+ spark properties. Flecainide (25 μM) induced sustained changes in Ca2+ sparks and waves in permeabilized ventricular myocytes, but in intact cells, 15 μM flecainide decreased wave frequency without affecting RyR2-dependent Ca2+ sparks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: